Literature DB >> 11895550

Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.

Tae-Bum Lee1, Young-Don Min, Sung-Chul Lim, Kyung-Jong Kim, Ho-Jong Jeon, Seok-Min Choi, Cheol-Hee Choi.   

Abstract

BACKGROUND AND AIMS: It has been proposed that the expression of Fas ligand (Fas L) in tumors may play an important role in immune escape. This study was undertaken to test a 'counterattack' theory as a mechanism of immune escape in gastric carcinoma.
METHODS: Expression of Fas and Fas L was examined in the human gastric cancer cell lines using reverse transcription-polymerase chain reaction. Cytotoxicity was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. Apoptosis of target Jurkat cells was examined after coculture with the effector gastric cancer cells in vitro. Immunohistochemical staining was performed for the detection of Fas and FasL in tumor-infiltrating lymphocytes (TIL) and gastric cancer cells in vivo. Apoptosis was detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) method in vitro and in vivo.
RESULTS: Fas and FasL mRNA were found to be differentially expressed in gastric cancer cell lines. The coculture experiment showed that apoptosis of Jurkat was induced by a FasL-overexpressing effector gastric cell SNU-484. In a Fas-expressing gastric cell SNU-638, Fas expression was upregulated by the treatment of gamma-interferon in a time- and concentration-dependent manner. SNU-638 treated with gamma-interferon was more sensitive to anti-Fas antibody-mediated cytotoxicity than was the control cell line, suggesting an increase of functional Fas in gastric cancer cells. The expression of FasL in gastric cancer cells and of Fas in apoptotic TIL was also detected in vivo.
CONCLUSION: The data indicate that the FasL expression of gastric cancer cells supports a 'counterattack theory' in gastric cancer cells and that the upregulation of Fas by IFN-gamma in SNU-638 may accelerate the apoptosis pathway through the Fas and FasL interaction between gastric cancer cells and immune cells. This result is supported by the expression of FasL in gastric cancer cells and apoptotic TIL in vivo. It is implicated that the different biological behaviors of gastric cancer cells could be at least in part explained by Fas and FasL interaction with immune cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895550     DOI: 10.1046/j.1440-1746.2002.02657.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer.

Authors:  Bo Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.

Authors:  Qian Li; Jie Peng; Xin-Hua Li; Ting Liu; Qing-Chun Liang; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

4.  FasL expression in colorectal carcinoma and its significance in immune escape of cancer.

Authors:  Qiang Tong; Ke Liu; Guobin Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

5.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

6.  Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Authors:  Yin Li; Da-Fu Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I.

Authors:  Gentaro Ito; Hiroaki Tanaka; Masaichi Ohira; Mami Yoshii; Kazuya Muguruma; Naoshi Kubo; Masakazu Yashiro; Nobuya Yamada; Kiyoshi Maeda; Tetsuji Sawada; Kosei Hirakawa
Journal:  Exp Ther Med       Date:  2012-04-02       Impact factor: 2.447

8.  Genetic variants in fas signaling pathway genes and risk of gastric cancer.

Authors:  Paula L Hyland; Shih-Wen Lin; Nan Hu; Han Zhang; Lemin Wang; Hua Su; Chaoyu Wang; Ti Ding; Ze-Zhong Tang; Jin-Hu Fan; You-Lin Qiao; Xiaoqin Xiong; William Wheeler; Carol Giffen; Kai Yu; Jeff Yuenger; Laurie Burdett; Zhaoming Wang; Stephen J Chanock; Margaret A Tucker; Sanford M Dawsey; Neal D Freedman; Alisa M Goldstein; Christian C Abnet; Philip R Taylor
Journal:  Int J Cancer       Date:  2013-09-11       Impact factor: 7.396

9.  Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.

Authors:  Mengsen Li; Xinhua Liu; Sheng Zhou; Pingfeng Li; Gang Li
Journal:  BMC Cancer       Date:  2005-08-05       Impact factor: 4.430

10.  The role of bone marrow mesenchymal stem cells in the treatment of acute liver failure.

Authors:  Shufang Yuan; Tao Jiang; Lihua Sun; Rongjiong Zheng; Nizam Ahat; Yuexin Zhang
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.